Canadian Pfizer partner sues Arbutus Biopharma over COVID-19 vaccine patent – National |

The biotech firm that makes mRNA-delivery know-how for Pfizer‘s PFE.N COVID-19 vaccine sued Arbutus Biopharma Corp ABUS.O in Manhattan federal courtroom on Friday, searching for to go off claims that the vaccine infringes Arbutus’ patents.

Canada-based Acuitas Therapeutics Inc stated Arbutus and companion Genevant Sciences have threatened to sue for doubtlessly billions of {dollars} in “unjustified royalties” over the vaccine Pfizer developed with Germany’s BioNTech SE BNTX.O.

Learn extra:

Pfizer to seek U.S. approval for 2nd COVID booster for people 65 and older: report

Acuitas requested the courtroom to seek out that the Pfizer/BioNTech vaccine doesn’t infringe Arbutus patents and that a number of Arbutus patents are invalid.

A consultant for Arbutus didn’t instantly reply to a request for touch upon Acuitas’ claims.

Story continues beneath commercial

Acuitas Chief Government Thomas Madden stated in a press release that the corporate stays assured in its know-how however in any other case declined to touch upon the lawsuit.

Click to play video: 'Health Canada approves Paxlovid, Pfizer’s COVID-19 pill'

Well being Canada approves Paxlovid, Pfizer’s COVID-19 tablet

Well being Canada approves Paxlovid, Pfizer’s COVID-19 tablet – Jan 17, 2022

The lawsuit is a part of a rising net of patent disputes over COVID-19 vaccine know-how. Arbutus sued Moderna MRNA.O over its mRNA know-how final month, however has not but sued Pfizer or Acuitas.

Pfizer and Moderna have been hit with patent lawsuits on Thursday by Alnylam Prescription drugs Inc ALNY.O, which argued its personal lipid nanoparticle mRNA-delivery know-how was “important” to each of the extensively used COVID-19 vaccines.

Pfizer stated final month that it anticipated $32 billion in income from its vaccine this 12 months. Moderna has stated its vaccine earned the corporate $17.7 billion in income in 2021.

— Reporting by Blake Brittain in Washington, D.C.

Leave a Comment